Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseasesPUBT·Aug 14 at 03:08 PMALMS-3.88%
Alumis' (ALMS) "Neutral" Rating Reaffirmed at HC WainwrightMarket Beat·Aug 14 at 12:48 PMALMS-3.88%BLK+0.52%
Alumis | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.662 MEarnings Watch·Aug 13 at 03:43 PMALMS-3.88%
Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 millionPUBT·Aug 13 at 03:01 PMALMS-3.88%
Alumis Psoriasis Treatment Shows Leading Skin Clearance Ratesbenzinga_article·Aug 11 at 08:57 AMALMS-3.88%
Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension studyPUBT·Aug 10 at 03:16 PMALMS-3.88%
High-flyer healthcare stocks: Ten names with strong momentum, weak valuationsMSN·Aug 10 at 08:05 AMACRS+3.13%ALMS-3.88%
Swiss National Bank Takes $2.81 Million Position in Alumis Inc. $ALMSMarket Beat·Jul 31 at 03:35 AMALMS-3.88%GS-C+0.12%
166,959 Shares in Alumis Inc. $ALMS Purchased by Ally Bridge Group NY LLCMarket Beat·Jul 29 at 02:12 AMALMS-3.88%
Alumis Chief Legal Officer Sanam Pangali disposes of common shares worth $140,000PUBT·Jul 8 at 03:41 PMALMS-3.88%
